Neulasta - (6mg/0.6mL; prefilled syringe)

Generic Name	Pegfilgrastim	Innovator	Amgen
Dosage	6mg/0.6mL; prefilled syringe	Branded US Sales	More Than $1000 mn
Probable FTF	None	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	More Than 5	Generic Launches	More Than 5
Indication	Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******			*******	******** *** *********	******** ** *** **, ****
******			*******	****	****** **** ********
*******			*******	******** ** *******	******** ** *** *, ****

Chronology Of Events